Published in J Control Release on February 23, 2001
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Nanoparticle-based targeted drug delivery. Exp Mol Pathol (2009) 2.62
Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev (2007) 1.92
Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine (2011) 1.58
Surface chemistry influences implant biocompatibility. Curr Top Med Chem (2008) 1.44
Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci (2008) 1.05
Dynamic factors controlling carrier anchoring on vascular cells. IUBMB Life (2011) 1.00
Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine (2010) 1.00
An in vitro release study of 5-fluoro-uracil (5-FU) from swellable poly-(2-hydroxyethyl methacrylate) (PHEMA) nanoparticles. J Mater Sci Mater Med (2009) 0.82
Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. Int J Nanomedicine (2011) 0.82
Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81
Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats. Int J Nanomedicine (2010) 0.81
AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci (2011) 0.80
Revolutionary impact of nanodrug delivery on neuroscience. Curr Neuropharmacol (2012) 0.79
Nanoparticle-based targeted therapeutics in head-and-neck cancer. Int J Med Sci (2015) 0.79
Biopolymeric nanoparticles. Sci Technol Adv Mater (2010) 0.78
Effect of grafting BMP2-derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells. J Tissue Eng Regen Med (2012) 0.78
Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes. Int J Nanomedicine (2014) 0.77
Nanocapsules: the weapons for novel drug delivery systems. Bioimpacts (2012) 0.77
Nanomedicine strategy for optimizing delivery to outer hair cells by surface-modified poly(lactic/glycolic acid) nanoparticles with hydrophilic molecules. Int J Nanomedicine (2016) 0.75
Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting-Ideal Versus Reality. Pharmaceuticals (Basel) (2016) 0.75
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection. J Neuroimmune Pharmacol (2016) 0.75
Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS PharmSciTech (2009) 0.75
Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics. Cancer Nanotechnol (2013) 0.75
Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cells. AAPS J (2014) 0.75
Transit of pharmaceutical dosage forms through the small intestine. Gut (1986) 2.35
PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release (1999) 2.08
Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87
Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res (1994) 1.61
Evaluation of impotence in older men. West J Med (1985) 1.54
The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res (1993) 1.53
Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun (1991) 1.50
Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst (1987) 1.42
Heavy metals in some Asian medicines and cosmetics. Public Health (1979) 1.42
Physicochemical properties of parenteral fat emulsions containing 20% triglyceride; Intralipid and Ivelip. J Clin Pharm Ther (1993) 1.40
Automated conductimetric titrimeter: use in studying ionic solute-solute interactions. J Pharm Sci (1975) 1.39
Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res (1994) 1.37
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35
Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30
Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res (1994) 1.30
Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci (1997) 1.28
Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 1.24
Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst (1994) 1.21
Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res (1991) 1.20
Chitosan microspheres prepared by spray drying. Int J Pharm (1999) 1.20
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19
Microparticles as potentially orally active immunological adjuvants. Vaccine (1989) 1.19
The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett (1992) 1.17
Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab (1990) 1.16
Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond) (2011) 1.14
Compliance in medication by Asian immigrants. Nurs Times (1979) 1.13
Lead poisoning and traditional practices: the consequences for world health. A study in Kuwait. Public Health (1981) 1.13
Transport of nanoparticles across the rat nasal mucosa. J Drug Target (2001) 1.11
Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol (1991) 1.09
Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res (1997) 1.08
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08
Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res (2002) 1.08
Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target (1993) 1.07
Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target (2001) 1.07
Lipid emulsions as drug delivery systems. Ann N Y Acad Sci (1987) 1.07
Epi-fluorescence microscopy and image analysis used to measure diffusion coefficients in gel systems. J Pharm Pharmacol (1992) 1.06
Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm (2000) 1.06
Controlled release microparticles for vaccine development. Vaccine (1991) 1.06
Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms. Int J Pharm (2004) 1.05
The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev (2001) 1.04
An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta (1993) 1.04
Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmacol (1984) 1.03
Techniques for the measurement of the rheological properties of sputum. Bull Physiopathol Respir (Nancy) (1973) 1.02
Diamorphine infusion in the preterm neonate. Arch Dis Child (1991) 1.02
Targeting of drugs and vaccines to the gut. Pharmacol Ther (1995) 1.02
The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett (1984) 1.00
Intranasal delivery of morphine. J Pharmacol Exp Ther (2002) 0.99
Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine (1995) 0.98
Structure and mucoadhesion of mussel glue protein in dilute solution. Biochemistry (1998) 0.98
The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release (1998) 0.97
Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res (1997) 0.97
Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul (1999) 0.97
Scientific principles in design of drug dosage formulations. Br Med J (1972) 0.96
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem (1996) 0.96
Sugar cross-linked gelatin for controlled release: microspheres and disks. Biomaterials (1998) 0.96
Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm (2001) 0.95
Physical properties and stability of two emulsion formulations of propofol. Int J Pharm (2001) 0.95
Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J Control Release (2009) 0.95
The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol (1984) 0.93
In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res (1992) 0.93
Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol (1988) 0.93
Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett (1994) 0.92
Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Dig Dis Sci (1993) 0.92
The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine (1999) 0.92
The rheological properties of sputum. Biorheology (1969) 0.92
Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release (1999) 0.92
Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. FEMS Microbiol Lett (1993) 0.91
Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br J Clin Pharmacol (1990) 0.91
Preparation of surface-modified albumin nanospheres. Biomaterials (1997) 0.91
Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc (1988) 0.91
Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release (2001) 0.91
The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci (2001) 0.90
Gastrointestinal transit of dosage forms in the pig. J Pharm Pharmacol (2001) 0.89
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89